Expanding applications of therapies based on GLP1
Approval: Semaglutide (specifically Wegovy) has received FDA approval for weight management
Seek urgent medical care if you experience persistently elevated blood glucose (above 300 mg/dL), symptoms of severe hyperglycemia (excessive thirst, frequent urination, fatigue), dehydration, or signs of diabetic ketoacidosis (nausea, vomiting, abdominal pain, rapid breathing, fruity breath odor)
You can tolerate uncertainty
STEP 3 : Combined semaglutide with intensive behavioral therapy, achieving mean weight loss of 16.0%
These medications are commonly prescribed for type 2 diabetes and for weight management, and clinicians counsel patients up front about potential nausea and other GI effects